Is There a Cancer Vaccine Available in the USA? Complete 2026 Evidence-Based Guide (FDA + NCI + ACS)

Short answer: Yes. In the United States as of 2026, there are two broad categories of cancer vaccines available: (1) preventive vaccines that stop cancer-causing infections — HPV vaccine (Gardasil 9) for cervical, anal, oropharyngeal, vulvar, vaginal, and penile cancers, and Hepatitis B vaccine for liver cancer prevention; and (2) therapeutic cancer vaccines used to treat existing cancer — BCG intravesical therapy for bladder cancer, Sipuleucel-T (Provenge) for metastatic prostate cancer, and Talimogene laherparepvec (T-VEC, Imlygic) for melanoma. Multiple mRNA-based personalised cancer vaccines (Moderna + Merck mRNA-4157, BioNTech BNT122) are in advanced Phase 3 trials and expected to receive FDA approval between 2026 and 2027.

Table of Contents

1. Two Categories of Cancer Vaccines
2. Preventive Cancer Vaccines — HPV
3. Hepatitis B Vaccine for Liver Cancer
4. Therapeutic Cancer Vaccines — BCG
5. Sipuleucel-T (Provenge) for Prostate Cancer
6. T-VEC (Imlygic) for Melanoma
7. mRNA Cancer Vaccines — The 2026 Frontier
8. How Therapeutic Vaccines Work
9. Who Can Get Them
10. Insurance Coverage
11. FAQs
12. References

1. Two Categories of Cancer Vaccines

When asking “is there a cancer vaccine available in the USA?” it is important to distinguish:

• Prophylactic (preventive) vaccines — target oncogenic viruses before infection: HPV, HBV
• Therapeutic (treatment) vaccines — stimulate the immune system to attack existing cancer cells: BCG, Sipuleucel-T, T-VEC, upcoming mRNA neoantigen vaccines

2. Preventive Cancer Vaccines — HPV (Gardasil 9)

Gardasil 9 is FDA-approved (2014; expanded 2018, 2020, 2023) for prevention of cancers caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, 58 plus genital warts types 6 and 11. The CDC’s ACIP recommends routine vaccination for ages 9–26 and shared clinical decision-making for 27–45. Three-dose schedule if initiated after age 15; two-dose schedule for ages 9–14.

Prevents: cervical cancer, oropharyngeal cancer, anal cancer, vulvar cancer, vaginal cancer, penile cancer, and genital warts. Real-world data from Scotland (2024) and Sweden show 90% reduction in cervical cancer among vaccinated cohorts. The HPV vaccine is the single most impactful cancer vaccine available in the USA.

3. Hepatitis B Vaccine for Liver Cancer

Chronic Hepatitis B virus (HBV) infection causes 50% of hepatocellular carcinoma (HCC) globally. The HBV vaccine (Engerix-B, Recombivax HB, Heplisav-B) is universally recommended by CDC ACIP for all infants, children, and all adults aged 19–59 (per 2022 update). Taiwan’s universal infant HBV vaccination programme reduced childhood HCC incidence by 80%.

4. Therapeutic Cancer Vaccines — BCG for Bladder Cancer

Bacillus Calmette-Guérin (BCG) is a live attenuated Mycobacterium bovis, FDA-approved since 1990 as intravesical immunotherapy for non-muscle-invasive bladder cancer (NMIBC), specifically high-grade Ta, T1, and carcinoma in situ (CIS). 70% complete response in CIS. Delivered weekly for 6 weeks (induction) followed by maintenance over 3 years per SWOG protocol. Mechanism: triggers a local Th1 immune response that recruits CD4+/CD8+ T cells and natural killer cells.

5. Sipuleucel-T (Provenge) for Prostate Cancer

Sipuleucel-T was the first FDA-approved autologous therapeutic cancer vaccine (2010). It is used for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC). The patient’s own dendritic cells are harvested via leukapheresis, pulsed ex vivo with PA2024 fusion protein (prostatic acid phosphatase + GM-CSF), and reinfused in 3 doses over 1 month. Median survival benefit 4.1 months (IMPACT trial, N Engl J Med 2010).

6. T-VEC (Imlygic) for Melanoma

Talimogene laherparepvec (T-VEC), approved 2015, is a genetically modified herpes simplex virus type 1 oncolytic injected directly into unresectable cutaneous, subcutaneous, or nodal melanoma lesions. It replicates in tumor cells, lyses them, and expresses GM-CSF locally to recruit antigen-presenting cells. Durable response rate ~16% (OPTiM trial).

7. mRNA Cancer Vaccines — The 2026 Frontier

Several personalised mRNA cancer vaccines are advancing:

• Moderna + Merck mRNA-4157 (V940) plus pembrolizumab in resected stage III/IV melanoma — Phase 2b (KEYNOTE-942) showed 44% reduction in recurrence; Phase 3 (INTerpath-001) ongoing with expected 2026–2027 readout
• BioNTech BNT122 (autogene cevumeran) for pancreatic ductal adenocarcinoma — early N Engl J Med data showed T-cell responses in 50% of vaccinated patients, extended recurrence-free survival
• mRNA-4157 and BNT113 for HPV-driven head and neck cancer

These leverage tumor neoantigen sequencing from a patient’s own tumor DNA + germline whole-exome sequencing. The FDA has granted Breakthrough Therapy status to mRNA-4157 (2023) and BNT122 (2024). Approval is widely expected in 2026 or 2027. This is a transformative moment — the honest answer to “is there a cancer vaccine available in the USA?” is about to broaden substantially.

8. How Therapeutic Vaccines Work

Therapeutic cancer vaccines stimulate the adaptive immune system to recognise tumor-associated antigens (TAAs) or tumor-specific neoantigens. Key mechanisms:

• Delivery of tumor antigens to dendritic cells
• Priming of cytotoxic CD8+ T cells and helper CD4+ T cells
• Overcoming the tumor microenvironment‘s immunosuppressive barriers (Tregs, MDSCs)
• Often combined with immune checkpoint inhibitors (pembrolizumab, nivolumab) for synergy

9. Who Can Get Them

• HPV vaccine: all ages 9–45, especially pre-sexual-debut adolescents
• HBV vaccine: universal; adults aged 19–59 per 2022 CDC update
• BCG: high-grade non-muscle-invasive bladder cancer
• Sipuleucel-T: asymptomatic/minimally symptomatic mCRPC
• T-VEC: unresectable stage IIIB-IV cutaneous melanoma
• mRNA trials: through clinical trials (ClinicalTrials.gov) in major US cancer centers — MD Anderson, Memorial Sloan Kettering, Dana-Farber, Mayo Clinic

10. Insurance Coverage

HPV and HBV vaccines are covered without copay under the Affordable Care Act (ACA) preventive services and VFC programme. BCG, Sipuleucel-T (US$93,000 per course), and T-VEC are covered under Medicare Part B and most commercial plans when FDA-indicated.

Related reading: See which micronutrient has the strongest cancer-prevention evidence in which vitamin is called anti-cancer.

11. External Video Resource

NCI: Cancer Vaccines Explained (YouTube)

12. FAQs

Q1. Is there a universal cancer vaccine?
Not yet. Each therapeutic vaccine targets a specific cancer or antigen. Research on pan-cancer neoantigen vaccines is active.

Q2. Is the HPV vaccine safe?
Yes — >500 million doses administered; the WHO, CDC, and FDA confirm safety; mild site reactions most common.

Q3. Can older adults get HPV vaccine?
Approved up to age 45 after shared clinical decision-making.

Q4. How much does Sipuleucel-T cost?
~US$93,000 for 3 infusions; usually covered by Medicare Part B.

Q5. Will mRNA vaccines replace chemotherapy?
Not replace, but increasingly combined with chemo + immunotherapy to improve survival.

Q6. Can I join an mRNA cancer vaccine trial?
Search ClinicalTrials.gov; ask your oncologist for referrals to NCI-designated centers.

Q7. Does BCG cure bladder cancer?
Not cure, but 50–70% complete response for high-grade NMIBC with CIS; reduces recurrence and progression.

13. Conclusion

So, is there a cancer vaccine available in the USA? Yes — several, with more coming. The HPV and HBV vaccines prevent six cancer types; BCG, Sipuleucel-T, and T-VEC treat existing bladder, prostate, and melanoma cancers; and personalised mRNA cancer vaccines for melanoma, pancreatic cancer, and other tumors are expected to reach FDA approval in 2026–2027. Immuno-oncology has turned the question from “if” to “how soon.”

14. References

1. FDA. Approved Cellular and Gene Therapy Products, 2024.
2. CDC. HPV ACIP Recommendations, 2024.
3. NCI. Cancer Vaccines Fact Sheet, 2024.
4. Weber JS et al. mRNA-4157 KEYNOTE-942. Lancet 2024.
5. Rojas LA et al. BNT122 pancreatic ductal adenocarcinoma. N Engl J Med 2023.
6. Kantoff PW et al. IMPACT trial. N Engl J Med 2010.

Medical Disclaimer: This article is for educational and informational purposes only and does not substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider regarding any medical condition or before making any decisions related to your health. Do not disregard or delay seeking professional advice based on information provided in this article.